A Phase 3 interventional study of Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump and Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump in Primary Amenorrhea With Hypogonadotropic Hypogonadism, sponsored by Ferring Pharmaceuticals. Completed at 35 sites in 2 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-03-03.
Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.
Among the 43 studies in Amenorrhea with a site in United States, this one is the 15th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2014, is one of 5 in phase 3, and was the 24th registered.
79 studies on the registry are indexed under Amenorrhea; 16 are open to participants now.
Browse Amenorrhea studies →7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–40 · Women only
University of Virginia · Sites in United States
Ages 14–30 · Women only
Massachusetts General Hospital · Sites in United States
Ages 14–30 · Women only
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 8–99
University of Colorado, Colorado Springs · Sites in United States
Ages 18–35 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 6 · Phase 4 2
First in 1989; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 54 across 49 interventional studies indexed under Amenorrhea.
Median enrollment 37 across the 30 interventional studies, 111 across the 13 observational. Of the 28 that completed or were terminated, 13 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 43 have an industry lead sponsor. The 10 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
Ferring Pharmaceuticals has 2 studies filed under Amenorrhea — fewer than ten, so there is no comparison to draw.
2 of the studies in Amenorrhea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00589654Memorial Sloan Kettering Cancer CenterMenstrual Cycle Maintenance and Quality of Life: A Prospective Study | 2026-12 |
| NCT05629377Mayo ClinicHypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH) | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Amenorrhea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the ovulation rate in women with primary amenorrhea with hypogonadotropic hypogonadism following pulsatile gonadotropin-releasing hormone (GnRH) treatment using the OmniPod pump versus placebo
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gonadorelin acetate 10 µg/pulse
Drug: Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump
Gonadorelin acetate 15 µg/pulse
Drug: Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump
Gonadorelin acetate 20 µg/pulse
Drug: Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump
Placebo
Drug: Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
Drug page: Gonadotropin-Releasing Hormone
Also known as: LutrePulse
Drug page: Gonadotropin-Releasing Hormone
Also known as: LutrePulse
Drug page: Gonadotropin-Releasing Hormone
Also known as: LutrePulse
Ovulation Rate
Calculated as a proportion of subjects with at least 1 post-baseline progesterone level ≥ 6 ng/mL or subjects with confirmed positive serum β-human chorionic gonadotropin (β-hCG) (i.e., 2 positive results) or subjects with a gestational sac documented by transvaginal ultrasound (TVUS).
Time frame: From treatment Day 1 up to 4 weeks after second positive β-hCG test, approximately 9 weeks
Progesterone (P4) Levels
Proportion of participants with at least 1 post-baseline P4 level ≥ 10 ng/mL.
Time frame: Treatment Days 19, 21, 23, 25, and 27
Clinical Pregnancy Rate
Proportion of subjects with presence of gestational sac and fetal heart movement on TVUS after a second positive serum β-hCG test.
Time frame: 2 to 4 weeks after a second positive serum β-hCG test
Biochemical Pregnancy Rate
Proportion of subjects with a confirmed positive serum β-hCG test after luteinizing hormone (LH) surge.
Time frame: Approximately 14 days after LH surge
LH Surge Detection
Proportion of subjects with a positive detection of LH surge, based on a Clearblue test which began when follicles with a mean diameter ≥14 mm were documented on TVUS.
Time frame: Daily from Day 11 until first positive LH surge or until Day 39
Ovarian Follicular Development: Number of Follicles With a Mean Diameter Greater Than or Equal to (≥)14 mm
Number of follicles with a mean diameter ≥14 mm collected from Days 10 or 11, until LH surge or Day 21.
Time frame: From treatment Day 10 to treatment Day 21
Ovarian Follicular Development: Number of Dominant Follicles With a Mean Diameter of ≥18 mm
Number of dominant follicles with a mean diameter ≥18 mm collected from Days 10 or 11, until LH surge or Day 21.
Time frame: From treatment Day 10 to treatment Day 21
Luteal Phase Support: Maximum P4 Levels
Maximum of post-dose P4 levels collected on treatment Days 19 to 27 are presented.
Time frame: Treatment Days 19, 21, 23, 25, and 27
Luteal Phase Support: Mean P4 Levels
Mean of post-dose P4 levels collected on treatment Days 19 to 27 are presented.
Time frame: Median post-dose P4 values across Treatment Days 19, 21, 23, 25, and 27
Change From Baseline in Follicle-stimulating Hormone (FSH)
FSH change from baseline in relation to the first dose (pulse) on Day 1 and Day 10
Time frame: Baseline (pre-dose), Treatment Day 1, Treatment Day 10
Change From Baseline in LH
LH change from baseline in relation to first dose (pulse) on Day 1 and Day 10
Time frame: Baseline (pre-dose), Treatment Day 1, Treatment Day 10
Mean Serum FSH and LH Levels
Mean FSH and LH levels on Day 1 and Day 10.
Time frame: Treatment Days 1 and Day 10
Estradiol (E2) Serum Levels
E2 serum levels on Day 1 and Day 10.
Time frame: At treatment Day 1 and Day 10
Type, Intensity, and Frequency of Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a subject taking part in a clinical trial. Proportion of subjects with any AE (serious or non-serious) and intensity of AEs (classified as mild, moderate or severe) are presented.
Time frame: From treatment Day 1 to end-of-trial, approximately 10 weeks
Hematology, Clinical Chemistry, and Urinalysis
Proportion of subjects with markedly abnormal changes in hematology, clinical chemistry, and urinalysis.
Time frame: From treatment Day 1 to end-of-trial, approximately 10 weeks
Frequency and Severity of Ovarian Hyperstimulation Syndrome (OHSS)
Proportion of subjects reporting OHSS classified as mild, moderate, or severe.
Time frame: From treatment Day 1 to end-of-trial, approximately 10 weeks
A total of 24 sites randomized subjects to the trial between April 2014 and February 2018. The trial sites that randomized subjects to the trial were: 22 in the United States of America and 2 in Canada.
| Milestone | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| Started | 10 | 9 | 10 | 10 |
| Dosed | 10 | 9 | 10 | 10 |
| Completed | 9 | 9 | 10 | 10 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Subject missed multiple doses of imp | 1 | 0 | 0 | 0 |
Calculated as a proportion of subjects with at least 1 post-baseline progesterone level ≥ 6 ng/mL or subjects with confirmed positive serum β-human chorionic gonadotropin (β-hCG) (i.e., 2 positive results) or subjects with a gestational sac documented by transvaginal ultrasound (TVUS).
| Participants | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Lutrepulse 15 μg/Pulse and 20 μg/Pulse Pooled | Placebo |
|---|---|---|---|---|---|
| Ovulation Rate | 1 | 4 | 5 | 9 | 0 |
Proportion of participants with at least 1 post-baseline P4 level ≥ 10 ng/mL.
| Participants | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Lutrepulse 15 μg/Pulse and 20 μg/Pulse Pooled | Placebo |
|---|---|---|---|---|---|
| Progesterone (P4) Levels | 1 | 4 | 3 | 7 | 0 |
Proportion of subjects with presence of gestational sac and fetal heart movement on TVUS after a second positive serum β-hCG test.
| Participants | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Lutrepulse 15 μg/Pulse and 20 μg/Pulse Pooled | Placebo |
|---|---|---|---|---|---|
| Clinical Pregnancy Rate | 0 | 2 | 5 | 7 | 0 |
Proportion of subjects with a confirmed positive serum β-hCG test after luteinizing hormone (LH) surge.
| Participants | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Lutrepulse 15 μg/Pulse and 20 μg/Pulse Pooled | Placebo |
|---|---|---|---|---|---|
| Biochemical Pregnancy Rate | 0 | 3 | 5 | 8 | 0 |
Proportion of subjects with a positive detection of LH surge, based on a Clearblue test which began when follicles with a mean diameter ≥14 mm were documented on TVUS.
| Participants | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Lutrepulse 15 μg/Pulse and 20 μg/Pulse Pooled | Placebo |
|---|---|---|---|---|---|
| LH Surge Detection | 3 | 7 | 6 | 13 | 0 |
Number of follicles with a mean diameter ≥14 mm collected from Days 10 or 11, until LH surge or Day 21.
| follicles | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| Day 10 | 0.0 (0 to 2) | 0.0 (0 to 1) | 0.0 (0 to 1) | 0.0 (0 to 0) |
| Day 12 | 0.0 (0 to 1) | 0.5 (0 to 1) | 0.0 (0 to 1) | 0.0 (0 to 0) |
| Day 15 | 0.0 (0 to 1) | 0.0 (0 to 1) | 0.0 (0 to 1) | 0.0 (0 to 0) |
| Day 18 | 0.0 (0 to 1) | 1.0 (0 to 1) | 1.0 (0 to 2) | 0.0 (0 to 0) |
| Day 21 | 0.0 (0 to 0) | 0.0 (0 to 0) | 0.0 (0 to 1) | 0.0 (0 to 0) |
Number of dominant follicles with a mean diameter ≥18 mm collected from Days 10 or 11, until LH surge or Day 21.
| follicles | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| Day 10 | 0.0 (0 to 0) | 0.0 (0 to 0) | 0.0 (0 to 0) | 0.0 (0 to 0) |
| Day 12 | 0.0 (0 to 0) | 0.0 (0 to 1) | 0.0 (0 to 1) | 0.0 (0 to 0) |
| Day 15 | 0.0 (0 to 1) | 0.0 (0 to 1) | 0.0 (0 to 1) | 0.0 (0 to 0) |
| Day 18 | 0.0 (0 to 1) | 0.0 (0 to 1) | 0.0 (0 to 1) | 0.0 (0 to 0) |
| Day 21 | 0.0 (0 to 1) | 0.0 (0 to 1) | 0.0 (0 to 0) | 0.0 (0 to 0) |
Maximum of post-dose P4 levels collected on treatment Days 19 to 27 are presented.
| ng/mL | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| Luteal Phase Support: Maximum P4 Levels | 0.40 (0.1 to 12.9) | 2.40 (0.4 to 18.5) | 8.00 (0.1 to 21.7) | 0.30 (0.1 to 0.4) |
Mean of post-dose P4 levels collected on treatment Days 19 to 27 are presented.
| ng/mL | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| Luteal Phase Support: Mean P4 Levels | 0.313 (0.10 to 8.06) | 1.440 (0.26 to 8.50) | 3.920 (0.10 to 14.80) | 0.233 (0.10 to 0.40) |
FSH change from baseline in relation to the first dose (pulse) on Day 1 and Day 10
| IU/L | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| FSH (Day 1) | 1.30 (0.0 to 7.7) | 5.40 (0.0 to 9.9) | 2.70 (0.0 to 5.7) | 0.10 (0.0 to 0.6) |
| FSH (Day 10) | 0.04 (-0.8 to 0.8) | -0.04 (-0.3 to 0.4) | 0.04 (-0.7 to 0.6) | -0.01 (-0.1 to 0.1) |
LH change from baseline in relation to first dose (pulse) on Day 1 and Day 10
| IU/L | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| Day 1 | 1.85 (0.2 to 22.6) | 7.90 (0.4 to 23.6) | 5.15 (0.6 to 12.4) | 0.05 (-0.2 to 0.3) |
| Day 10 | 0.00 (-2.9 to 1.6) | 0.58 (-1.7 to 1.9) | 0.03 (-0.9 to 1.7) | 0.00 (-1.0 to 0.0) |
Mean FSH and LH levels on Day 1 and Day 10.
| IU/L | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| FSH (Baseline) | 1.59 ± 1.793 | 1.47 ± 1.112 | 2.48 ± 2.235 | 1.35 ± 1.520 |
| FSH (Day 1) | 3.64 ± 4.010 | 6.20 ± 3.929 | 5.38 ± 2.565 | 1.52 ± 1.673 |
| FSH (Day 10) | 4.00 ± 1.495 | 5.07 ± 2.530 | 5.24 ± 1.124 | 1.67 ± 1.796 |
| LH (Baseline) | 0.54 ± 0.669 | 0.27 ± 0.179 | 0.93 ± 0.954 | 0.73 ± 1.063 |
| LH (Day 1) | 6.27 ± 9.507 | 8.82 ± 7.348 | 6.12 ± 3.745 | 0.79 ± 1.026 |
| LH (Day 10) | 4.12 ± 3.931 | 4.69 ± 2.692 | 4.07 ± 2.335 | 0.82 ± 1.037 |
E2 serum levels on Day 1 and Day 10.
| pmol/L | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| Day 1 (pre-dose) | 36.50 (36.5 to 169.0) | 88.00 (36.5 to 147.0) | 81.00 (36.5 to 92.0) | 122.50 (36.5 to 198.0) |
| Day 10 (pre-dose) | 106.00 (36.5 to 697.0) | 202.00 (84.0 to 499.0) | 136.00 (36.5 to 323.0) | 128.00 (36.5 to 224.0) |
An AE was defined as any untoward medical occurrence in a subject taking part in a clinical trial. Proportion of subjects with any AE (serious or non-serious) and intensity of AEs (classified as mild, moderate or severe) are presented.
| Participants | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| Any AE | 5 | 3 | 4 | 4 |
| Non-serious AE | 5 | 3 | 4 | 4 |
| Serious AE | 0 | 0 | 0 | 0 |
| Intensity (Mild) | 5 | 1 | 2 | 1 |
| Intensity (Moderate) | 0 | 2 | 2 | 2 |
| Intensity (Severe) | 0 | 0 | 0 | 1 |
Proportion of subjects with markedly abnormal changes in hematology, clinical chemistry, and urinalysis.
| participants | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| Hematology | 0 | 0 | 0 | 0 |
| Serum chemistry (Sodium, <=130 mmol/L) | 0 | 1 | 0 | 0 |
| Urinalysis (Protein,mg/dL, -ve to +ve [post-dose]) | 2 | 0 | 1 | 0 |
| Urinalysis (Specific Gravity <=1.005) | 0 | 1 | 1 | 0 |
Proportion of subjects reporting OHSS classified as mild, moderate, or severe.
| participants | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| Frequency and Severity of Ovarian Hyperstimulation Syndrome (OHSS) | 0 | 0 | 0 | 0 |
Collected over Treatment-emergent AEs (TEAEs) occurred after the start of IMP administration and within 5 days after the last dose, or a pre-treatment AE or pre-existing medical conditioning the worsened in intensity after the start of IMP and within 5 days after the last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LutrePulse 10 µg/Pulse | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| LutrePulse 15 µg/Pulse | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| LutrePulse 20 µg/Pulse | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Placebo | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| Event | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo |
|---|---|---|---|---|
| Breast tendernessReproductive system and breast disorders | 0/10 | 2/8 | 2/10 | 0/11 |
| Hot flushesVascular disorders | 0/10 | 1/8 | 2/10 | 0/11 |
| Abdominal pain lowerGastrointestinal disorders | 0/10 | 1/8 | 0/10 | 0/11 |
| NauseaGastrointestinal disorders | 0/10 | 1/8 | 1/10 | 0/11 |
| HeadacheNervous system disorders | 1/10 | 1/8 | 0/10 | 0/11 |
| Mood swingsPsychiatric disorders | 0/10 | 1/8 | 1/10 | 0/11 |
| Adnexa uteri painReproductive system and breast disorders | 0/10 | 1/8 | 0/10 | 0/11 |
| PruritusSkin and subcutaneous tissue disorders | 0/10 | 1/8 | 0/10 | 0/11 |
| Abdominal discomfortGastrointestinal disorders | 0/10 | 0/8 | 1/10 | 0/11 |
| Abdominal distesionGastrointestinal disorders | 0/10 | 0/8 | 1/10 | 1/11 |
The intent-to-treat (ITT) analysis set comprised all randomized subjects.
| Age, Continuous(years) | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 30.9 ± 4.20 | 29.6 ± 6.02 | 30.9 ± 5.67 | 29.5 ± 2.55 | 30.2 ± 4.63 |
| Sex: Female, Male(Participants) | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo | Total |
|---|---|---|---|---|---|
| Female | 10 | 9 | 10 | 10 | 39 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 1 | 3 | 9 |
| Not Hispanic or Latino | 7 | 7 | 9 | 7 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 | 0 | 4 |
| White | 9 | 7 | 7 | 8 | 31 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| BMI(kg/m^2) | LutrePulse 10 µg/Pulse | LutrePulse 15 µg/Pulse | LutrePulse 20 µg/Pulse | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 29.41 ± 6.065 | 23.70 ± 4.567 | 26.53 ± 4.218 | 23.85 ± 3.953 | 25.93 ± 5.159 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2014 to primary completion in Feb 2018, 46 months.
Results were first posted in Mar 2021, 3 years after primary completion. A results delay was requested in Jan 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gonadotropin-Releasing Hormone